Skip to main content
メニュー
Revvity logo
Contact us

Loading...

JP
Search all

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Rapid screening of novel therapeutics by ImmuSignature™ T cell activation assay
t-cell-activation-app-note1920x640
Application Note

Rapid screening of novel therapeutics by ImmuSignature™ T cell activation assay

T cells are critical for cell-mediated immunity and their impaired function correlates with various diseases. Insufficient T cell proliferation and activation can lead to the development of cancer and infectious diseases, while overactivation can result in transplant rejections, autoimmune diseases, and allergies.

This application note describes the development of a robust T cell activation assay to aid assessing the impact of novel therapeutics on T cell function to accelerate drug discovery and development.

For research use only. Not for use in diagnostic procedures.

Download Resource

Rapid screening of novel therapeutics by ImmuSignature™ T cell activation assay

Download Application Note
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.